biostudies-literatureUnknown12Ke QOvarian cancer has the worst prognosis among major gynecological cancers. Current therapies include platinum, Taxol, angiogenesis inhibitors, and poly[ADP-ribose]polymerase (PARP) inhibitors. However, resistance develops in most ovarian cancer patients. Identification of more pro-tumor factors in ovarian cancer may provide insights into ovarian cancer biology and therapy. In this study, we find ZKSCAN3, a zinc-finger transcription factor, is overexpressed in ovarian cancer. We show that ZKSCAN3 promotes ovarian cancer cell proliferation. Through RNA-Seq and chromatin immunoprecipitation (ChIP)-seq, HSPB1 is identified as a target gene of ZKSCAN3. HSPB1 expression is significantly decreased upon suppressing ZKSCAN3 expression. Suppressing HSPB1 expression also inhibits ovarian cancer cell pFrontiers in molecular biosciences1623062https://www.ebi.ac.uk/biostudies/studies/S-EPMC12698437biostudies-literatureZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.PMC12698437Sun LLi ZFan LKe QSong TLi NZhao HfalseZKSCAN3 promotes ovarian cancer cell proliferation by increasing HSPB1 expression.Ovarian cancer has the worst prognosis among major gynecological cancers. Current therapies include platinum, Taxol, angiogenesis inhibitors, and poly[ADP-ribose]polymerase (PARP) inhibitors. However, resistance develops in most ovarian cancer patients. Identification of more pro-tumor factors in ovarian cancer may provide insights into ovarian cancer biology and therapy. In this study, we find ZKSCAN3, a zinc-finger transcription factor, is overexpressed in ovarian cancer. We show that ZKSCAN3 promotes ovarian cancer cell proliferation. Through RNA-Seq and chromatin immunoprecipitation (ChIP)-seq, HSPB1 is identified as a target gene of ZKSCAN3. HSPB1 expression is significantly decreased upon suppressing ZKSCAN3 expression. Suppressing HSPB1 expression also inhibits ovarian cancer cell p2025-01-01T00:00:00Z20252026-06-06T02:57:41.675Z2026-05-25T03:07:33.889ZS-EPMC126984374139350710.3389/fmolb.2025.1623062